PF4 and COVID-19: Since aPL and anti-PF4 antibodies were reported in few COVID-19 patients (12, 17) and anti-PF4 antibodies have been associated with the development of VITT after ChAdOx1 vaccination (13–15), we detected the abovementioned autoantibodies in our cohort of vaccinated healthcare workers.